Arbutus Biopharma Corporation

Financials

Mittelzufluss aus laufender Geschäftstätigkeit -10.31 M-13.39 M-15.75 M-5.82 M-4.68 M -39.64 M Mittelzufluss aus Investitionstätigkeit 13.41 M11.35 M15.61 M-10.02 M-1.36 M 15.58 M Zahlungsströme aus der Finanzierungstätigkeit 1.42 M2.78 M453 K844 K1.64 M 5.72 M Freier Cashflow -10.4 M-13.39 M-15.75 M-5.82 M-4.68 M -39.64 M

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007.

ABUS

Financials

Arbutus Biopharma Corporation

Nachrichten

Arbutus Biopharma: EPS übertrifft Schätzungen um 0,02 $ - Umsatz besser als erwartet

Roivant Sciences-Aktie erreicht Allzeithoch von 30,31 USD/n

Moderna reaches $950 million settlement with Arbutus and Genevant over patent litigation

Why Moderna’s $950M Patent Bill Is A Small Price For Pipeline Freedom (NASDAQ:MRNA)

Arbutus Biopharma: Chardan bestätigt Kaufempfehlung nach Vergleich mit Moderna/n

Chardan reiterates Arbutus Biopharma stock rating on Moderna deal

MRNA Stock Gains on $2.25B Deal to Settle Patent Dispute With ROIV, ABUS

Moderna rises as up to $2.25 billion settlement for COVID vaccine patent dispute to remove overhang

Moderna shares jump as settlement removes major legal overhang

Stock Market Today: Dow, Nasdaq Higher; Bitcoin Surges On Trump News (Live Coverage)

CrowdStrike, Nvidia and Moderna rise premarket; Abercrombie & Fitch falls

Roivant Sciences: H.C. Wainwright hebt Kursziel nach Milliardenvergleich auf 34 US-Dollar an